Clinical profile and outcomes in glioblastoma multiforme: Institutional experience.

Abstract

e12501 Background: The standard of care for glioblastoma is surgical resection followed by adjuvant RT (radiotherapy) with concurrent and adjuvant temozolomide. Methods: Between January 2006 to December 2010, patients of glioblastoma who underwent surgery and RT to a dose of 60 Gy were analysed retrospectively. Age, KPS, extent of surgery, RPA class were noted and patients were divided into two groups, RT alone (Group I) or RT with concurrent temozolomide 75mg/m2/day followed by adjuvant temozolomide 150 mg/m2/dayX5days q28days for 6 cycles(Group II). Results: A total of 62 patients were analysed, 23 patients in group I and 39 in group II. Median age in group I was 48 years (range 16-60, 19 male, 4 female), 8(34.8%) patients underwent gross total resection, 12 (52.2%) had partial resection and 3(13%) had stereotactic biopsy. The median overall survival (OS) was six months. Median age in group II was 50 years (range 13-76, 26 male, 13 female), 17(43.6%) patients underwent gross total resection, 19(48.7%) had partial resection and 3 (7.7%) had stereotactic biopsy. The median OS was nine months (p=0.018). Patients were analysed according to the RPA class (III-VI). Median OS and 1 yr survival for group I for RPA class III,IV,V/ VI were 12, 6 and 4 months and 50%,15.3%,0% respectively. Median OS and 1 yr survival rates for group II for RPA class III, IV,V / VI were 20, 8 and 5.5 months and 66.6%, 35%, 30% respectively. On multivariate analysis age(p=0.005), KPS(p=0.05), extent of surgery(p=0.043) were found to affect survival. Conclusions: Concurrent radiotherapy and temozolomide followed by adjuvant temozolomide results in improved survival in glioblastoma.